Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial

JAMA Oncology

Volumn 3, Issue 10, 2017, Pages

  Scurr, Martin ^a   Pembroke, Tom ^a   Bloom, Anja ^a   Roberts, David ^a   Thomson, Amanda ^a   Smart, Kathryn ^a   Bridgeman, Hayley ^a   Adams, Richard ^b   Brewster, Alison ^b   Jones, Robert ^b   Gwynne, Sarah ^c   Blount, Daniel ^d   Harrop, Richard ^d   Wright, Melissa ^a   Hills, Robert ^a   Gallimore, Awen ^a   Godkin, Andrew ^a,e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

^d OXFORD BIOMEDICA UK LTD   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; ONCOFETAL ANTIGENS; TUMOR ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFORMED CONSENT; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OPEN STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; AGED; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 85031750528     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2579     Document Type: Article

References (31)

1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4): 524-548.
2. Cancer Research UK. Cancer Statistics Report: Cancer Mortality in the UK in 2012. http://www.cancerresearchuk.org/health-professional/cancer -statistics/statistics-by-cancer-type/bowel-cancer /survival. 2014. Accessed March 4, 2017.
3. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266-273.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
5. Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266): 1387-1390.
6. Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology. 2015;4(7):e1058597.
7. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61(1):89-95.
8. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66(5):867-869.
9. + T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut. 2012;61(8):1163-1171.
10. + T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunol Res. 2013;1(6).
11. + T cell dependent and antibody mediated. Cancer Immunol Immunother. 2006;55 (9):1081-1090.
12. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12(11, pt 1):3416-3424.
13. Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non–small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212-223.
14. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5): 641-648.
15. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72(14): 3439-3444.
16. Maughan TS, James RD, Kerr DJ, et al; Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457-464.
17. Harrop R, Chu F, Gabrail N, Srinivas S, Blount D, Ferrari A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother. 2013;62(9): 1511-1520.
18. Radojcic V, Bezak KB, Skarica M, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010;59(1):137-148.
19. Curtin JF, Candolfi M, Fakhouri TM, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One. 2008;3(4):e1983.
20. + T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679-684.
21. + tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022-3029.
22. + regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010;126(11):2635-2643.
23. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186-192.
24. Hindley JP, Jones E, Smart K, et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 2012;72(21):5473-5482.
25. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One. 2006;1:e129.
26. Correale P, Rotundo MS, Botta C, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res. 2012;18(3):850-857.
27. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13(15, pt 1):4487-4494.
28. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16(22):5539-5547.
29. Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol. 2011;18(3): e150-e157.
30. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695-1710.
31. + regulatory T cells. Mucosal Immunol. 2014;7(2):428-439.